Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANRO
SellHot AirAlto Neuroscience, Inc. · Healthcare · United States · $1.4B · Avg Vol: $15M/d
COMPANY DESCRIPTION
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company pioneering precision psychiatry through its proprietary Precision Psychiatry Platform. The company's competitive moat is built on its AI-driven analysis of brain biomarkers, EEG, and behavioral data to match patients with targeted drug candidates. It operates as a niche innovator aiming to revolutionize treatment for depression and other mental health conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -2.13 | -1.42 | -2.50 | -2.19 | — | -2.32 | -2.92 | -3.29 | — |
| Shares | 25.6M | 25.6M | 27.0M | 31.9M | +24.8% | 39.2M | — | — | — |
| Debt | 9.7M | 10.0M | 16.9M | 24.0M | 35.0% | 23.3M | — | — | — |
| Equity | -38.4M | -71.7M | 151.5M | 151.1M | -0.2% | — | — | — | — |
| Op CF | -20.4M | -33.4M | -47.4M | -51.8M | — | -68.3M | — | — | — |
| Inv CF | -0.7M | -0.5M | -2.1M | -24.0K | — | — | — | — | — |
| Fin CF | 43.8M | 68.1M | 135.7M | 60.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANRO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANRO | Alto Neuroscience, Inc.(you) | $1.4B | 32 | Sell |
| LBRX | LB Pharmaceuticals Inc | $1.5B | 32 | Sell |
| APMD | Apnimed, Inc. | $1.2B | 32 | Sell |
| BCAX | Bicara Therapeutics Inc. | $1.6B | 30 | Sell |
| ANAB | AnaptysBio, Inc. | $1.7B | 34 | Sell |
| SLDB | Solid Biosciences Inc. | $1.0B | 33 | Sell |
| CGEM | Cullinan Therapeutics, Inc. | $1.3B | 26 | Sell |
| AGIO | Agios Pharmaceuticals, Inc. | $2.0B | 32 | Sell |
| FBRX | Forte Biosciences, Inc. | $1.6B | 28 | Sell |
| JANX | Janux Therapeutics, Inc. | $1.1B | 28 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%